U.S. markets closed

Andina Acquisition Corp. III (ANDAW)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3900-0.0100 (-2.50%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4000
Open0.4210
Bid0.2900 x 800
Ask0.4160 x 1800
Day's Range0.3801 - 0.4100
52 Week Range0.3801 - 0.4100
Volume52,704
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      EMMAC Life Sciences Group Secures GDP licence for Swiss pharmaceutical entity, EMMAC SAGL Approved to import, distribute and export medicinal products for domestic, EU and international markets

      LONDON, Aug. 18, 2020 (GLOBE NEWSWIRE) -- EMMAC Life Sciences Group (”EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company, is pleased to announce that EMMAC SAGL, the Group’s pharmaceutical entity in  Switzerland, has secured its Good Distribution Practice (“GDP”) licence for the distribution of medicinal products. EMMAC now has the ability to import, distribute and export medicinal products, including medical cannabis, for the domestic Swiss, EU and international markets.  EMMAC currently holds multiple research, cultivation and GMP licences across its vertically integrated business in Europe, which is experiencing increasing demand for premium-quality medical cannabis products. The European medical cannabis market is predicted to be worth in excess of $8 billion by 2023.1Antonio Costanzo, CEO of EMMAC, said: “This is another important milestone for EMMAC and one that positions us well to meet the requirements of the domestic Swiss market as regulation evolves, and caters to the growing demand from international markets for high-quality medical cannabis. We continue to execute at pace, realising our vision of establishing EMMAC as Europe’s largest independent cannabis company, and shaping the future of medical cannabis.”On 22 July 2020, EMMAC announced the Company had signed a non-binding letter of intent related to a business combination with Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina”), pursuant to which EMMAC would become a publicly traded company on the NASDAQ Stock Exchange with EMMAC’s shareholders rolling over all of their equity in EMMAC into the combined public company. As consideration for the transaction, it is anticipated that the current EMMAC shareholders would collectively own a majority of the equity of the combined public company.___________ 1 Source: Brightfield Group – European CBD and Cannabis Market 2019 Report &  Canaccord (2018) + Cowen Data for U.S. CBD Market Applied to Europe (2023)About EMMAC Life Sciences Group EMMAC Life Sciences Group is Europe’s largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information about EMMAC, please visit https://www.emmac.com/Contact: For scientific enquiries please contact research@emmac.com For general enquiries please contact info@emmac.com or visit www.emmac.comMedia enquiries:Buchanan   Henry Harrison-Topham / Jamie Hooper / Ariadna PeretzTel: +44 (0) 20 7466 5000   emmac@buchanan.uk.com www.buchanan.uk.com       CAUTIONARY STATEMENT All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

    • GlobeNewswire

      EMMAC Life Sciences Group (”EMMAC” or the “Group” or the “Company”) Medalchemy receives licence for cultivation of medical cannabis

      Spanish EU GMP Facility now has licences to cultivate, extract and manufacture cannabis extract  EMMAC now licensed to cultivate medical cannabis in Portugal and Spain  LONDON, July 28, 2020 (GLOBE NEWSWIRE) -- EMMAC Life Sciences Group, Europe’s largest independent cannabis company, is pleased to announce that Medalchemy, the Group’s Good Manufacturing Practice (“GMP”) certified manufacturing site in Alicante, Spain has secured approval from the Spanish Health Authorities (“AEMPS”) to cultivate medical cannabis. Medalchemy now has fully integrated cannabis supply facilities, with a licence to grow medical cannabis commercially as well as extract and manufacture cannabis extract as an active pharmaceutical ingredient (“API”).EMMAC holds two medical cannabis cultivation licences, one in Spain, at Medalchemy, and the second in Portugal, at its primary cultivation site Terra Verde, which in 2020 has produced and exported c.2 tonnes of medical cannabis flower. EMMAC now holds multiple medical cannabis licences in 4 countries across Europe.Antonio Costanzo, CEO of EMMAC, said: “This latest licence to cultivate medical cannabis at our EU-GMP Facility in Alicante strengthens EMMAC’s position as the leading European independent cannabis company with two culitivation facilities and an alternative point of supply for our business. With full control of our supply chain we are able to ensure a consistent, reliable and high-quality product that our growing customer base can trust. As European legislation quickly evolves to reflect the growing body of medical evidence regarding the benefits of medical cannabis, EMMAC’s integrated business model positions it well to capitalise on the high-growth potential of this valuable market.”Last week, EMMAC announced that the Company signed a non-binding letter of intent related to a business combination with Andina Acquisition Corp. III (NASDAQ: ANDA, ANDAW, and ANDAU) (“Andina”), pursuant to which EMMAC would become a publicly traded company on the NASDAQ Stock Market with EMMAC’s shareholders rolling over all of their equity in EMMAC into the combined public company. As consideration for the transaction, it is anticipated that the current EMMAC shareholders would collectively own a majority of the equity of the combined public company.About EMMAC Life Sciences Group EMMAC Life Sciences Group is Europe’s largest independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC’s vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information about EMMAC, please visit https://www.emmac.com/Contact: For scientific enquiries please contact research@emmac.com For general enquiries please contact info@emmac.com or visit www.emmac.comMedia enquiries:Buchanan  Henry Harrison-Topham / Jamie Hooper / Ariadna PeretzTel: +44 (0) 20 7466 5000 emmac@buchanan.uk.comwww.buchanan.uk.com CAUTIONARY STATEMENT All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

    • INTERVIEW: European Cannabis Leader EMMAC Gets Lifted Through a SPAC
      IPO-Edge.com

      INTERVIEW: European Cannabis Leader EMMAC Gets Lifted Through a SPAC

      EMMAC Executive Chairman Lorne Abony By Jarrett Banks EMMAC Life Sciences, Europe’s largest cannabis company, will go public through a merger with Andina Acquistion Corp. III, giving U.S. investors access to the white-hot medical cannabis sector in Europe. EMMAC signed a letter of intent to combine with the special purpose acquisition company, or SPAC, to […]